Department of Allergy and Clinical Immunology, Federal University of São Paulo, Brazil.
Am J Rhinol Allergy. 2010 Jan-Feb;24(1):e32-6. doi: 10.2500/ajra.2010.24.3427.
Our objective was to evaluate the action of topical nasal steroid in nasal congestion and nasal hyper-reactivity in children and adolescents with persistent allergic rhinitis.
Twenty atopic children and adolescents (6 to 18 years) with moderate-to-severe persistent allergic rhinitis (PAR) were treated with mometasone furoate (100 microg once a day) for 21 days. At the beginning and end of treatment, the following were recorded: a) nasal symptoms score; b) several parameters of nasal congestion measured by acoustic rhinometry (SRE 2000 Rhinometrics); c) degree of nasal hyper-reactivity to histamine (concentration of histamine necessary to induce at least 100% increase in total nasal resistance during nasal provocation test). Data were compared with those from 20 controls.
Compared to controls, PAR patients had significantly higher score of symptoms, as well as higher degree of nasal hyper-reactivity and lower nasal volumes. After treatment, there was a significant decrease in the mean nasal symptoms score (8.0 versus 3.8; p < 0.001) and in the nasal hyper-reactivity (histamine concentration: 0.72 mg/ml versus 2.60 mg/ml; p < 0.001). Congestion improvement was observed by the increase in all acoustic rhinometry parameters. Among all studied volumes, the volume in the segment between 2 and 5 cm showed the highest mean increase (19.8%).
Treatment with topical nasal steroid objectively reduced nasal congestion and nasal histamine hyper-reactivity in children and adolescents with PAR.
评估局部鼻腔皮质类固醇对持续性变应性鼻炎患儿和青少年鼻塞和鼻高反应性的作用。
20 例中至重度持续性变应性鼻炎（PAR）的特应性儿童和青少年（6-18 岁）接受糠酸莫米松（100μg，每天一次）治疗 21 天。在治疗开始和结束时，记录以下内容：a）鼻症状评分；b）声鼻测量法（SRE 2000 Rhinometrics）测量的鼻塞多项参数；c）对组胺的鼻高反应性程度（鼻激发试验中引起总鼻阻力至少增加 100%所需的组胺浓度）。将数据与 20 名对照者进行比较。
与对照组相比，PAR 患者的症状评分明显更高，鼻高反应性和鼻体积也更高。治疗后，平均鼻部症状评分（8.0 对 3.8；p<0.001）和鼻高反应性（组胺浓度：0.72mg/ml 对 2.60mg/ml；p<0.001）显著降低。通过所有声鼻测量法参数的增加，观察到鼻塞改善。在所有研究的体积中，2 至 5cm 之间的体积平均增加最多（19.8%）。
局部鼻腔皮质类固醇治疗可客观地减轻 PAR 患儿和青少年的鼻塞和鼻内组胺高反应性。
